Combination of cldn18.2 and gucy2c targeted antagonist therapy
EP4747364A1Pending Publication Date: 2026-05-27LEGEND BIOTECH USA INC +1
Patent Information
- Authority / Receiving Office
- EP · EP
- Patent Type
- Applications
- Current Assignee / Owner
- LEGEND BIOTECH USA INC
- Filing Date
- 2024-07-19
- Publication Date
- 2026-05-27
AI Technical Summary
Technical Problem
Current CAR-T therapies targeting CLDN18.2 have relatively short median progression-free survival (mPFS) due to antigen loss and tumor heterogeneity, leading to tumor recurrence and disease progression.
Method used
A combination of CLDN18.2 and GUCY2C targeted antagonist therapy using engineered immune cells expressing multi-specific chimeric antigen receptors (CARs) that simultaneously target both antigens, enhancing tumor recognition and elimination.
Benefits of technology
The combination therapy potentially improves treatment efficacy by targeting multiple antigens, thereby reducing the likelihood of tumor escape mechanisms and enhancing the durability of clinical responses.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure PCTCN2024106351-FTAPPB-I100001 
Figure PCTCN2024106351-FTAPPB-I100002 
Figure PCTCN2024106351-FTAPPB-I100003
Abstract
Provided is a method for treating a tumor in a subject in need thereof, comprising administering an effective amount of a combination of a CLDN18.2 antagonist and a GUCY2C antagonist, or an antagonist of CLDN18.2 and GUCY2C to the subject. The present disclosure also provides multi-specific chimeric antigen receptor constructs, combination of chimeric antigen receptors, engineered immune cells, and methods of use thereof. The present disclosure further relates to activation and expansion of cells for therapeutic uses, especially for chimeric antigen receptor-based T cell immunotherapy.
Need to check novelty before this filing date? Find Prior Art